Philippa C Matthews1, Amy L Chue, David Wyllie, Adam Barnett, Tomide Isinkaye, Lorrayne Jefferies, Andrew Lovering, Matthew Scarborough. 1. Oxford Bone Infection Unit, Oxford University Hospitals NHS Trust, Nuffield Orthopaedic Centre, Windmill Road, Headington, Oxford OX3 7HE, UK; Department of Infectious Diseases and Microbiology, Oxford University Hospitals NHS Trust, John Radcliffe Hospital, Headley Way, Oxford OX3 9DU, UK; Peter Medawar Building for Pathogen Research, Nuffield Department of Medicine, South Parks Road, Oxford OX1 3SY, UK. Electronic address: p.matthews@doctors.org.uk.
Abstract
OBJECTIVE: Teicoplanin is widely used for the treatment of severe gram-positive infection, aiming to achieve trough serum levels of 20-60 mg/L for patients with severe infection. A standard 400 mg daily dose is frequently associated with sub-therapeutic levels, and we have therefore changed our routine approach to 600 mg daily (following loading doses in each case). We set out to investigate the impact of this dose increase on drug levels and potential side-effects. METHODS: We undertook a retrospective study of 549 consecutive adult Out-Patient Antimicrobial Treatment (OPAT) episodes treated with intravenous teicoplanin. RESULTS: Therapeutic teicoplanin levels were more frequently achieved in patients treated with 600 mg compared to 400 mg daily (68% vs. 37% respectively, p < 0.0001), without an increased frequency of potentially toxic levels, defined as >60 mg/L (6% vs. 8% respectively, p = 0.4). There was no difference in the incidence of neutropaenia, eosinophilia, thrombocytopaenia, acute renal injury or treatment cessation in patients treated with the higher teicoplanin dose. CONCLUSIONS: In the majority of stable adult patients with normal renal function, we advocate a loading regimen (600 mg b.d. for two doses) followed by a 600 mg daily teicoplanin dose in order to achieve therapeutic trough levels.
OBJECTIVE: Teicoplanin is widely used for the treatment of severe gram-positive infection, aiming to achieve trough serum levels of 20-60 mg/L for patients with severe infection. A standard 400 mg daily dose is frequently associated with sub-therapeutic levels, and we have therefore changed our routine approach to 600 mg daily (following loading doses in each case). We set out to investigate the impact of this dose increase on drug levels and potential side-effects. METHODS: We undertook a retrospective study of 549 consecutive adult Out-Patient Antimicrobial Treatment (OPAT) episodes treated with intravenous teicoplanin. RESULTS: Therapeutic teicoplanin levels were more frequently achieved in patients treated with 600 mg compared to 400 mg daily (68% vs. 37% respectively, p < 0.0001), without an increased frequency of potentially toxic levels, defined as >60 mg/L (6% vs. 8% respectively, p = 0.4). There was no difference in the incidence of neutropaenia, eosinophilia, thrombocytopaenia, acute renal injury or treatment cessation in patients treated with the higher teicoplanin dose. CONCLUSIONS: In the majority of stable adult patients with normal renal function, we advocate a loading regimen (600 mg b.d. for two doses) followed by a 600 mg daily teicoplanin dose in order to achieve therapeutic trough levels.
Authors: T Ueda; Y Takesue; K Nakajima; K Ichiki; A Doita; Y Wada; T Tsuchida; Y Takahashi; M Ishihara; H Ikeuchi; M Uchino; T Kimura Journal: Eur J Clin Microbiol Infect Dis Date: 2016-06-09 Impact factor: 3.267
Authors: Hannah Dabrowski; Helena Wickham; Surjo De; Jonathan Underwood; Stephen Morris-Jones; Sarah Logan; Michael Marks; Gabriele Pollara Journal: Int J Antimicrob Agents Date: 2020-01-08 Impact factor: 5.283
Authors: Ann L N Chapman; Sanjay Patel; Carolyne Horner; Helen Green; Achyut Guleri; Sara Hedderwick; Susan Snape; Julie Statham; Elizabeth Wilson; Mark Gilchrist; R Andrew Seaton Journal: JAC Antimicrob Resist Date: 2019-08-26
Authors: V Ramos-Martín; M N Neely; K Padmore; M Peak; M W Beresford; M A Turner; S Paulus; J López-Herce; W W Hope Journal: Antimicrob Agents Chemother Date: 2017-09-22 Impact factor: 5.191